Completing Trials Disrupted By COVID-19: Strategies And Solutions From Expert Statisticians

The outbreak of the coronavirus pandemic has resulted in epic trial disruptions across the spectrum of clinical development. Since March, Cytel’s statisticians have advised on a number of trials confronting skewed or missing data, unexpected comorbidities, patient recruitment and retention challenges, unanticipated interim looks, updated Statistical Analysis Plans, and a range of other difficulties impeding trial completion.

Here we summarize the most common questions confronting Cytel’s clients and outline strategic solutions provided by our expert statisticians.